公司股票自2025年9月29日(星期一)开市起停牌1天，将于2025年9月30日(星期二)开市起复牌。公司股票 自2025年9月30日(星期二)被实施其他风险警示，股票简称由"美晨科技"变更为"ST美晨";股票代码不 变，仍为"300237";实施其他风险警示后，股票交易日涨跌幅限制不变，仍为20%。 美晨科技（300237）(300237.SZ)发布公告，根据中国证券监督管理委员会山东监管局(简称"山东证监 局")下发的《行政处罚事先告知书》(﹝2025﹞9号)(简称"《告知书》")以及《深圳证券交易所创业板股 票上市规则》第9.4条规定："上市公司出现下列情形之一的，本所对其股票交易实施其他风险警示： (七)根据中国证监会行政处罚事先告知书载明的事实，公司披露的年度报告财务指标存在虚假记载，但 未触及第10.5.2条第一款规定情形，前述财务指标包括营业收入、利润总额、净利润、资产负债表中的 资产或者负债科目"，公司股票交易将被实施其他风险警示，但未触及《深圳证券交易所创业板股票上 市规则》第十章第五节规定的重大违法强制退市的情形。 ...

Core Viewpoint - ST Tian Sheng (002872) has been under other risk warnings since June 5, 2019, due to the alleged misappropriation of company funds by its controlling shareholder Liu Qun, who has been ordered to repay a total of 125,074,926 yuan [1] Group 1: Stock Performance - As of September 10, 2025, ST Tian Sheng closed at 4.79 yuan, up 0.42% from the previous trading day, with a total market capitalization of 1.523 billion yuan [1] - The stock opened at 4.75 yuan, reached a high of 4.81 yuan, and a low of 4.74 yuan, with a trading volume of 839.29 thousand yuan and a turnover rate of 0.82% [1] Group 2: Legal and Financial Developments - Liu Qun was sentenced to repay 91.824926 million yuan for misappropriated funds and 33.25 million yuan for misused funds, totaling 125,074,926 yuan [1] - As of April 8, 2021, all principal and interest of the funds occupied by Liu Qun had been fully repaid [1] - On December 29, 2023, the Chongqing First Intermediate People's Court confirmed the misappropriation and misused funds, and Liu Qun has returned the funds [1] - The Chongqing High People's Court upheld the original ruling on August 8, 2024, dismissing Liu Qun's appeal [1] - Beijing Xinghua Accounting Firm issued a qualified opinion on the company's 2024 financial report due to an ongoing investigation by the CSRC regarding information disclosure violations [1] - The company is cooperating with the investigation while maintaining normal production and operations [1]

Core Viewpoint - Jilin Yalian Development Technology Co., Ltd. has applied to the Shenzhen Stock Exchange to revoke the other risk warning on its stock after completing the necessary rectifications related to previous administrative penalties [1] Group 1 - The company held a board meeting on August 18, 2025, to review and approve the application for the revocation of the stock trading risk warning [1] - The stock was suspended from trading on August 5, 2024, due to false disclosures in its annual report, and was later subject to other risk warnings, changing its stock abbreviation to "ST Yalian" [1] - The company has completed the rectifications related to the administrative penalty and has been more than twelve months since the penalty decision was made, with no other risk warning conditions present [1]

Core Viewpoint - ST Xifa (000752) has announced that certain risk warning situations have been eliminated in its 2024 annual report, and it does not trigger delisting risk warnings [1] Group 1 - The application to revoke certain risk warnings has been approved by the Shenzhen Stock Exchange [1] - The previously implemented risk warning situations have not all been eliminated, and the stock abbreviation and daily price fluctuation limits remain unchanged [1] Group 2 - The net profit attributable to the parent company's shareholders for 2024 is 26.1963 million yuan, while the net profit after deducting non-recurring gains and losses is 27.4149 million yuan [1]

Core Viewpoint - A listed company in Shenzhen faced a significant operational impact due to its subsidiary's non-compliance with GMP standards, leading to a production and sales suspension, which resulted in a stock price drop to the daily limit [1] Group 1: Company Impact - The subsidiary generated revenue of 216.57 million yuan and a net loss of 14.00 million yuan in 2024, accounting for 60.09% of the listed company's revenue and 9.8% of its consolidated net profit, indicating a substantial impact on the parent company's operations [1] - The company may face other risk warnings if the subsidiary's production does not resume within three months, as per the Shenzhen Stock Exchange's regulations [1] Group 2: Social Responsibility - Companies in the pharmaceutical sector must prioritize social responsibility and product safety, as the quality of drugs directly affects public health [2] - The concept of "pharmaceutical ethics" should guide the operations of pharmaceutical companies, balancing profit maximization with stakeholder interests [2] Group 3: Recommendations for Improvement - It is recommended that pharmaceutical companies innovate their internal governance by establishing independent quality control committees to oversee production processes and ensure compliance with GMP standards [2] - Companies should enhance their social responsibility disclosures, especially in cases of significant incidents or regulatory actions, to maintain transparency and accountability [3] - The trading rules should be revised to provide clearer criteria for implementing risk warnings, ensuring that the exchange, rather than the company, determines the necessity for such warnings [3] Group 4: Conclusion - Pharmaceutical companies must embed the principle of "quality is life" into their governance structures and operational practices to succeed in both capital markets and public health demands [4]